Form 4: C4 Therapeutics Director Acquires Stock Options

Director Ronald Harold Wilfred Cooper acquires stock options in C4 Therapeutics, Inc.

Summary

• Ronald Harold Wilfred Cooper, a director of C4 Therapeutics, Inc. (CCCC), acquired stock options on June 7, 2024.
• The options grant the right to buy 65,000 shares of common stock at an exercise price of $4.66.
• The options vest over time, with 33% vesting on June 7, 2025, and the remainder vesting in equal quarterly installments thereafter, contingent upon continued service.
• Following the transaction, Cooper directly owns 65,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is a common practice. The vesting schedule suggests a long-term commitment from the director.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings in the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's increased stake in the company.

Key Dates